Evaluation of Serum Human Epididymis Protein 4 Levels in Women with Polycystic Ovary Syndrome

被引:2
作者
Hancerliogullari, Necati [1 ]
Tokmak, Aytekin [1 ]
Pekcan, Meryem Kuru [2 ]
Oksuzoglu, Aysegul [2 ]
Candar, Tuba [3 ]
Ustun, Yaprak [2 ]
机构
[1] Zekai Tahir Burak Womens Hlth Educ & Res Hosp, Obstet & Gynecol, Ankara, Turkey
[2] Zekai Tahir Burak Womens Hlth Educ & Res Hosp, Obster & Gynecol, Ankara, Turkey
[3] Ufuk Univ, Med Biochem, Ankara, Turkey
关键词
human epididymis protein 4; gynecological cancers; polycystic ovary syndrome; ovarian cancer; diagnosis; TUMOR-MARKER; CANCER RISK; HE-4; EXPRESSION; ENDOMETRIAL; PREVALENCE; CRITERIA; BENIGN;
D O I
10.7759/cureus.5736
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim The main purpose of this study is the determination of scrum epididymis protein 4 (HE4) levels in women diagnosed with polycystic ovary syndrome (PCOS) and comparison with non-PCOS healthy controls. Methods All consecutive women, who applied between January 2017 and June 2017 to the gynecology outpatient clinics at the Zekai Tahir Burak Women's Health Training and Research Hospital and met the study criteria, were included in this cross-sectional study. Serum human epididymis protein 4 (HE4) concentrations were measured in each woman and the mean values were compared between the PCOS and non-PCOS groups. Results A total of 90 women (45 with PCOS and 45 without PCOS) were included in the final analysis. There were no statistically significant differences between the groups in terms of age and body mass index (p >0.05). Basal scrum HE4 levels were 172.8 +/- 139.8 and 131.8 +/- 123.1 pmol/L in the PCOS and non-PCOS groups, respectively (p = 0.415). Conclusion The serum HE4 levels were found to be similar in women with and without PCOS. No significant correlation was observed between PCOS parameters and scrum HE4 levels.
引用
收藏
页数:9
相关论文
共 25 条
[1]   The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report [J].
Azziz, Ricardo ;
Carmina, Enrico ;
Dewailly, Didier ;
Diamanti-Kandarakis, Evanthia ;
Escobar-Morreale, Hector F. ;
Futterweit, Walter ;
Janssen, Onno E. ;
Legro, Richard S. ;
Norman, Robert J. ;
Taylor, Ann E. ;
Witchel, Selina F. .
FERTILITY AND STERILITY, 2009, 91 (02) :456-488
[2]   Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis [J].
Barry, John A. ;
Azizia, Mallika M. ;
Hardiman, Paul J. .
HUMAN REPRODUCTION UPDATE, 2014, 20 (05) :748-758
[3]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[4]   Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients [J].
Bignotti, E. ;
Ragnoli, M. ;
Zanotti, L. ;
Calza, S. ;
Falchetti, M. ;
Lonardi, S. ;
Bergamelli, S. ;
Bandiera, E. ;
Tassi, R. A. ;
Romani, C. ;
Todeschini, P. ;
Odicino, F. E. ;
Facchetti, F. ;
Pecorelli, S. ;
Ravaggi, A. .
BRITISH JOURNAL OF CANCER, 2011, 104 (09) :1418-1425
[5]   The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms [J].
Bingle, L ;
Singleton, V ;
Bingle, CD .
ONCOGENE, 2002, 21 (17) :2768-2773
[6]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[7]   Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas [J].
Drapkin, R ;
von Horsten, HH ;
Lin, YF ;
Mok, SC ;
Crum, CP ;
Welch, WR ;
Hecht, JL .
CANCER RESEARCH, 2005, 65 (06) :2162-2169
[8]   Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases [J].
Escudero, Jose M. ;
Auge, Jose M. ;
Filella, Xavier ;
Torne, Aureli ;
Pahisa, Jaume ;
Molina, Rafael .
CLINICAL CHEMISTRY, 2011, 57 (11) :1534-1544
[9]  
FUTTERWEIT W, 1988, Comprehensive Therapy, V14, P12
[10]   Polycystic ovary syndrome and gynecological cancers: Is there a link? [J].
Gadducci, A ;
Gargini, A ;
Palla, E ;
Fanucchi, A ;
Genazzani, AR .
GYNECOLOGICAL ENDOCRINOLOGY, 2005, 20 (04) :200-208